Aug 25 (Reuters) - Noxopharm Ltd (NOX) :
- NOXOPHARM PHASE I CLINICAL TRIAL SHOWS ANTI-INFLAMMATORY RESPONSE IN COVID-19 PATIENTS
- NOXOPHARM - STARTED DISCUSSIONS TO ADD VEYONDA TO ONE OF GLOBAL CLINICAL TRIAL PROGRAMS TO IDENTIFY EFFECTIVE ANTI-INFLAMMATORY THERAPIES IN COVID-19
Add to My Watchlist
What is My Watchlist?